lilly oral glp-1 FDA seeks safety data for Lilly's oral GLP-1 Foundayo

Orforglipron, Eli Lilly's investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line data released by the company. http://ms.spr.ly/6182SBSaC

24.12

★★★★☆4.8 (126)

FDA approves Eli Lilly's new weight loss pill Foundayo

23.30

★★★★★4.9 (98)

Head-to-head trial shows Eli Lilly's oral GLP-1 orforglipron outperforms oral semaglutide

26.08

★★★★★5.0 (157)

Founday (orforglipron), the new oral GLP-1 pill for weight loss, now available in the U.S. - Eli Lilly

22.11

★★★★★4.7 (84)

Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill

24.28

★★★★★4.9 (203)

Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating

20.64

★★★★★5.0 (176)

FDA Approved: Orforglipron (Foundayo) — Oral GLP-1 Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide

24.10

★★★★★4.8 (132)